India Pharma Outlook Team | Thursday, 25 June 2026
Translational Research could be the key to unlocking the next phase of growth for India's pharmaceutical sector, according to a new white paper that highlights major gaps in the country's innovation ecosystem.
While India has established itself as a global leader in generic medicines and vaccine manufacturing, experts believe Translational Research remains the missing link between laboratory discoveries and commercially successful healthcare products.
The white paper, released by the Biotechnology Industry Research Assistance Council (BIRAC) in collaboration with industry stakeholders, calls for urgent action to strengthen India's ability to convert scientific research into market-ready drugs, diagnostics, medical devices, and healthcare technologies.
India has a strong base of scientists, academic institutions, startups, and pharmaceutical companies. However, many promising discoveries fail to move beyond the research stage due to infrastructure gaps, funding challenges, and limited collaboration among stakeholders.
Also Read: Scaling Perfusion Technology from Lab Success to Manufacturing Reality
The report states that despite growing investments in Pharma Innovation and Drug Discovery, the country lacks a well-connected Research Ecosystem that can support products through every stage of development.
Several challenges continue to slow progress:
According to the white paper, strengthening these areas could help accelerate innovation and improve the success rate of research projects moving from laboratories to the market.
The report also highlights the need for stronger collaboration between research institutions, startups, investors, pharmaceutical companies, and government agencies. Such partnerships can help reduce development timelines and improve access to resources required for commercialization.
The white paper recommends building a stronger Innovation Ecosystem through targeted investments and policy support.
Key focus areas include:
Experts believe these measures can help bridge the gap between scientific discovery and product development while encouraging greater participation from startups and biotech companies.
The report also points to the growing importance of Biotechnology, advanced therapies, precision medicine, and digital health technologies. Building capabilities in these areas could help India compete more effectively in the global healthcare market.
India's pharmaceutical industry has gained global recognition for affordable medicines and large-scale manufacturing. However, future growth is expected to depend increasingly on innovation-led development rather than volume-based production alone.
A stronger Translational Research framework could enable the country to create more intellectual property, develop innovative therapies, attract global investment, and generate high-value jobs. It could also improve the ability of domestic companies to address emerging healthcare challenges through locally developed solutions.
Industry experts believe that with the right policy support, infrastructure, and funding mechanisms, India can strengthen its position in global Healthcare Innovation and become a major center for research-driven pharmaceutical development.
The white paper concludes that building an effective Research Ecosystem is essential for transforming scientific breakthroughs into real-world healthcare solutions and ensuring long-term competitiveness for the Pharma Industry.
.jpg)
